1st March 2012, Belfast, UK: Malignant melanoma (MM), the most dangerous type of skin cancer, is caused mainly by intense episodes of UV exposure and originates in the pigment-producing melanocytes in the basal layer of the epidermis. Early detection and complete excision of the primary lesions is crucial for reducing melanoma-related deaths but current diagnostic practice is highly subjective. This leads to unnecessary surgical procedures, which are highly-invasive and expensive.
Now, Takashi Nagaoka and a team of Japanese researchers have developed an automated, non-invasive melanoma screening system that may eliminate the need for a morphological examination and reduce needless surgery. Their Diffuse Reflectance Hyperspectral Imaging technique determines the levels and position of melanin and haemoglobin at the molecular level. The hyperspectral imaging data allows the team to differentiate between melanomas and other pigmented skin lesions based on this molecular pigmentary level.
“Since our first priority was to establish whether or not hyperspectral imaging data could be used for melanoma screening, we needed a camera of the highest possible sensitivity. The only camera that met our requirements was the Andor iXon EMCCD camera,” says Takashi Nagaoka of the Shizuoka Cancer Center Research Institute, Japan. “The iXon successfully captured cutaneous spectra in the visible to near infrared range that contain physiological information about melanin and haemoglobin within the melanoma lesion. Our melanoma discrimination index measures the variegation in spectra.
“Having established a workable index to identify malignant melanomas, the exciting possibility of a rapid screening system for general practitioners or other primary care providers is raised. We are working on such a system using the Andor Luca camera and believe it will enable non-specialist operators to identify PSLs that require further investigation or excision, saving both time and money. The Andor Software Development Kit supplied with the iXon camera speeded up the original research and the validation of the index. Now, it is reducing the time needed to develop our second-generation system as only minimal changes were required to adapt for the Luca camera.”
According to Antoine Varagnat, Product Specialist at Andor, “Non-invasive skin cancer screening has been the focus for an increasing number of research groups recently, illustrated by the development of bespoke instruments based on Hyperspectral imaging - such as the one described by Nagaoka-San’s group - or hyphenated Raman-OCT as reported by a US-Dutch team led by Anita Mahadevan at Vanderbilt University. The high sensitivity and speed of both the iXon EMCCD and Newton NIR-optimized Deep-Depletion cameras, as well as the ease of integration of these detectors in complex, demanding clinical setups, have enabled the development of the next generation of high-throughput, patient-friendly diagnosis instruments. By making this type of diagnosis much more accessible and routine in a wide variety of clinical environments, early detection of malignant skin lesions and subsequent early treatment of these lesions should greatly increase diagnosed patients survival rate.&r dquo;
Andor’s modular Spectroscopy solutions encompass a wide range of high performance CCD, ICCD, and EMCCD detectors, as well as a comprehensive range of Research-grade spectrograph platforms and versatile interfacing to microscopes or complex instrumentation, such as demanding process control or medical/clinical environments. To learn more about the iXon camera series and their use in spectroscopy, please visit the Andor website iXon pages [www.andor.com/scientific_cameras/ixon_emccd_camera] and spectroscopy pages [www.andor.com/spectroscopy_solutions].
1. Takashi Nagaoka, Atsushi Nakamura, Haruka Okutani, Yoshio Kiyohara & Takayuki Sota. “A possible melanoma discrimination index based on hyperspectral data: a pilot study,” Skin Research and Technology; 0: 1–10 (2011)
2. Chetan A. Patil, Harish Kirshnamoorthi, Darrel L. Ellis, Ton G. van Leeuwen, and Anita Mahadevan-Jansen “A Clinical Instrument for Combined Raman Spectroscopy-Optical Coherence Tomography of Skin Cancers,” Lasers in Surgery and Medicine 43:143–151 (2011)
About Andor Technology
Andor is a world leader in Scientific Imaging, Spectroscopy Solutions and Microscopy Systems. Established in 1989 from Queen's University in Belfast, Northern Ireland, Andor Technology now employs over 300 people in 16 offices worldwide, distributing its portfolio of over 80 products to 10,000 customers in 55 countries.
Using the latest cutting edge technologies, Andor designs and manufactures robust, high performance instruments allowing scientists around the world to measure light down to a single photon and capture events occurring within 1 billionth of a second. This unique capability is helping them push back the boundaries of knowledge from nano-scale to universe-scale level in fields as diverse as drug discovery, new material development and analysis, medical diagnosis, food quality control, art restoration, astronomy and solar energy research.
More information about Andor Technology PLC (LSE: AND) is available at the company's website [www.andor.com].
For further information, please contact Andor Technology direct or their marketing agency, Catalyst Communications.
Andor Technology plc.
7 Millennium Way
Springvale Business Park
Belfast BT12 7AL
+44 (0) 28 9027 0812
2 Crispin Way
Buckinghamshire SL2 3UE
+44 (0) 1753 648 140